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Getting drug doses right in children with
tuberculosis (TB)
H. McIlleron
University of Cape Town, Cape Town, South Africa
New drugs that could revolutionize the treatment of drug-
sensitive anddrug-resistant TB are imminently available.Moreover
recent research of pharmacokinetic-pharmacodynamic relation-
ships in adults suggests that the doses of some currently used
drugs should be changed. It is imperative that children access these
improvements to TB treatment without delay.
It is likely that children will respond well to a TB regimen if
given drug formulations and doses that achieve comparable phar-
macokinetics to those in adults. Recent changes to theWHO-dosing
guidelines for the ﬁrst line TB drugs in children acknowledge that
the traditional approach to pediatric dosing (using mg/kg doses
approximating those in adults) resulted in under-dosing of chil-
dren fordecades. Efﬁcientpharmacokinetic studies arenecessary to
support safe and effective doses for children. Contemporarymodel-
based pharmacometric analyses facilitate efﬁcient studies, pooling
of data across different studies, and prediction of pragmatic dosing
approaches.
Pediatric studies designed to describe the pharmacokinetics of
new drugs need to be conducted during drug development, typi-
cally as soon as phase 2b studies in adults have been completed.
The studies should include sufﬁcient data in children across the
range of ages, and should preferably be conducted in the target
pediatric populationusing appropriate child-friendly formulations,
which should be developed early.
Treatment preparation and administration methods practiced
by caregivers of infants and young children could affect the sta-
bility and bioavailability of the drugs administered. There is little
knowledge of these practices, or treatment acceptability and taste
preferences, which should be taken into account when developing
suitable formulationsandpragmatic adviceondoseadministration.
Drug-drug interactions complicate the management of HIV and
other comorbid conditions in children with TB. As the magnitude
of pharmacokinetic drug-drug interactions may not be predicted
by adult studies, studies in children are required to guide dose
adjustments.
The optimization of doses and formulations for children will
improve care and cannot continue to be neglected.
http://dx.doi.org/10.1016/j.ijid.2014.03.535
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Lost in translation - what next for studies of
new TB vaccines for children?
B. Kampmann
Imperial College London and MRC Unit, The Gambia,
London, United Kingdom
Professor Kampmann leads a research team of clinicians and
scientists in theUKandWestAfrica. Her grouphas beenworking on
the difﬁcult problem of childhood tuberculosis and has evaluated
immune responses to natural infection and vaccination, including
novel diagnostics. Her overviewpresentation todaywill summarise
recent accomplishments in thedevelopmentofnewvaccineagainst
TB, why these might or might not work and what lessons can be
learned from the recent Phase IIb trial of a new anti-TB vaccine in
South Africa, which unfortunately- or maybe predictively- did not
show any protective efﬁcacy in young children. She will present
her thoughts on where this leaves the ﬁeld now and what the next
steps might be. She would not expect that everyone agrees.
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Whole-genome sequencing for TB drug
resistance determination
S.V. Omar1,∗, J. Featherston2, H. Said1, Z. Bhyat1,
A. Dreyer1, J. Rees2, N. Ismail1
1 National Institute for Communicable Diseases,
Johannesburg, South Africa
2 Agricultural Research Council, Pretoria, South
Africa
Background: South Africa remains challenged with a high
Tuberculosis burden accompanied by a steady increase in drug-
resistant cases. The introductionof twomolecularmethodsover the
past ﬁve year has improved the detection of drug-resistant cases,
however, providing information for only one or two drugs used
for ﬁrst-line treatment. In this study we access the usefulness of
Whole Genome Sequencing (WGS) for Drug Resistance determina-
tion of both ﬁrst and second line drugs used for the treatment of M.
tuberculosis in high burdened South Africa
Methods & Materials: Pilot work involved WGS on a set of
twenty M. tuberculosis isolates with known phenotypic resistance
proﬁles on liquid medium. Sequencing was carried out using the
MiSeq next-generation sequencer (Illumina), library preparation
was performed using the NexteraXT kit and sequencing using
the version 2 kit (500 cycle). Sequence analysis was carried out
